Moderna Joins Top S&P 500 Firms as Stock Value Triples

Bloomberg2021-07-22

(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile. The move caps the drugmaker’s transformation from an early-stage biotech to...

网页链接
免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • Guardian91
    2021-07-22
    Guardian91
    Vaccination is more of a necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. 🤔
  • Shank88
    2021-07-22
    Shank88
    The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.
  • 377tkr
    2021-07-22
    377tkr
    How true?
  • xiaochan
    2021-07-22
    xiaochan
    Wow! Go go go!! 
  • TriciaChang
    2021-07-22
    TriciaChang
    Ok
  • QqSM
    2021-07-22
    QqSM
    Great summary. Thanks
发表看法
15